Enteric sustained-release preparation containing zaltoprofen and preparation method thereof

A technology for zaltoprofen and sustained-release preparations, which is applied in the field of enteric-coated sustained-release preparations and its preparation, and can solve problems such as poor reproducibility of release between batches, poor fluidity, and unsuitability for industrial production.
CN102048680AInactive Publication Date: 2011-05-11HEBEI AOXING GROUP PHARMA
3 Cites 8 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
HEBEI AOXING GROUP PHARMA
Publication Date
2011-05-11
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a new formulation of novel nonsteroidal antiinflammatory medicament-zaltoprofen, namely an enteric sustained-release preparation containing zaltoprofen. Matrix which is insoluble in water and is insoluble in gastrointestinal fluid is used as a sustained-release auxiliary material to prepare the enteric sustained-release preparation. The enteric sustained-release preparation prepared in the invention has no fast release phenomenon of the medicament, and the repeatability of in vitro medicament release action of the preparation with different batches is good, so as to bebeneficial to keep in-vivo plasma concentration of a patient stable after taking the medicament.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to an enteric-coated sustained-release preparation and a preparation method thereof, in particular to an enteric-coated sustained-release preparation of a novel non-steroidal anti-inflammatory drug zaltoprofen and a preparation method thereof. Background technique

[0002] Zaltoprofen is a non-steroidal anti-inflammatory drug with anti-inflammatory, analgesic and antipyretic effects. It mainly works by inhibiting the synthesis of prostaglandins and blocking inflammatory mediators. It is used for the treatment of pain and rheumatoid Musculoskeletal disorders such as arthritis. The drug was developed by Chemiphar Corporation of Japan, and it was first listed in Japan in 1993. From 2003 to 2004, another 8 companies went on the market to sell the product. The product was launched in South Korea in 1999.

[0003] The analgesic effect of this product and the effect on acute inflammation are strong, and it is also effective on subacute...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More